Alps Advisors Inc. purchased a new stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Rating) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 27,040 shares of the company’s stock, valued at approximately $385,000. Alps Advisors Inc. owned 0.06% of PMV Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Nisa Investment Advisors LLC purchased a new stake in PMV Pharmaceuticals in the 1st quarter worth about $25,000. Los Angeles Capital Management LLC lifted its stake in PMV Pharmaceuticals by 55.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 19,450 shares of the company’s stock worth $405,000 after acquiring an additional 6,900 shares in the last quarter. Swiss National Bank lifted its stake in PMV Pharmaceuticals by 8.5% in the 1st quarter. Swiss National Bank now owns 26,800 shares of the company’s stock worth $558,000 after acquiring an additional 2,100 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of PMV Pharmaceuticals by 3.7% during the 1st quarter. Principal Financial Group Inc. now owns 618,926 shares of the company’s stock worth $12,886,000 after purchasing an additional 21,964 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of PMV Pharmaceuticals by 1.2% during the 1st quarter. JPMorgan Chase & Co. now owns 3,205,487 shares of the company’s stock worth $66,739,000 after purchasing an additional 38,265 shares in the last quarter.
PMV Pharmaceuticals Stock Up 5.0 %
PMVP opened at $10.25 on Wednesday. PMV Pharmaceuticals, Inc. has a fifty-two week low of $8.99 and a fifty-two week high of $25.10. The business has a 50-day moving average of $11.71 and a 200-day moving average of $13.16.
Analyst Upgrades and Downgrades
PMV Pharmaceuticals Profile
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
- Get a free copy of the StockNews.com research report on PMV Pharmaceuticals (PMVP)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.